Screener
Regeneron Pharmaceuticals REGN Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 6:52 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000872589-26-000025
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accrued expenses and other current liabilities | 2,966.5 | 2,876.4 |
| Finance lease liabilities | 720.0 | — |
| Deferred revenue | 684.8 | 553.0 |
| Total current liabilities | 5,530.6 | 4,368.4 |
| Long-term debt | 1,986.6 | 1,985.9 |
| Finance lease liabilities | — | 720.0 |
| Deferred revenue | 220.4 | 208.7 |
| Other noncurrent liabilities | 2,281.6 | 2,018.8 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Regeneron Pharmaceuticals's total current liabilities?
- Regeneron Pharmaceuticals (REGN) reported total current liabilities of $5.53B in Q2 2026.
- How has Regeneron Pharmaceuticals's total current liabilities changed year-over-year?
- Regeneron Pharmaceuticals's total current liabilities increased by 50.8% year-over-year, from $3.67B to $5.53B.
- What is the long-term trend for Regeneron Pharmaceuticals's total current liabilities?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's total current liabilities has grown at a 10.1% compound annual growth rate (CAGR), from $2.7B to $4.37B.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Regeneron Pharmaceuticals's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude